NASDAQ · Biotechnology · USD

Avalyn Pharma Inc. (AVLN) Stock Analysis

Avalyn Pharma Inc. (AVLN) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

AVLN

$37.39

+$1.95 (+5.50%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare AVLN with… →

AVLN Key Statistics

As of Sep 4, 2026

Trading

Open: $35.21
Previous Close: $35.44
Day's Range: 34.90–38.34
52-Week Range: 24.15–40.17
Volume: 243.50K

Valuation

Market Cap: $1.66B
P/E Ratio: unprofitable
EPS (ttm): −2.33

Financials (FY)

Revenue (FY): $0.00
Net Income (FY): −$85.20M
Profit margin: 0.00%
Shares Outstanding: 44.33M

Dividend and dates

Earnings Date: November 16, 2026estimated
Avg Volume: 315.45K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

AVLN Revenue and Earnings by Fiscal Year

FY ends December

Fiscal year	Revenue	Net income	Net margin
2025	$0.00	−$85.20M	—
2024	$0.00	−$49.74M	—

Fiscal year	Revenue	Gross profit	Operating income	Net income	Net margin
2025	$0.00	—	−$91.29M	−$85.20M	—
2024	$0.00	—	−$57.12M	−$49.74M	—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

AVLN Valuation vs Biotechnology Median

Median of 656 stocks

Metric	AVLN	Biotechnology median	vs median
Profit margin	0.00%	0.00%	0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

The market values Avalyn Pharma Inc. (AVLN) at $1.66B. The company sits in the Healthcare sector, in the Biotechnology industry. Headcount on file is 55.

The 52-week range on file runs from $24.15 to $40.17. AVLN last closed at $37.39 on September 4, 2026. That is +$1.95 (+5.50%) against the previous close. The latest close sits 54.82% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $0.00. The same year closed with a net loss of $85.20M. Profit margin runs at 0%. Trailing earnings per share are −2.33.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative.

Growth & Income

No dividend is on file for AVLN.

So far in 2026 the price is +26.79%.

Peer Comparison

Avalyn Pharma Inc. (AVLN) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company	Ticker	Market Cap	P/E Ratio
Avalyn Pharma Inc.	AVLN	$1.66B	—
Vertex Pharmaceuticals Incorporated	VRTX	$138.42B	32.5
Regeneron Pharmaceuticals, Inc.	REGN	$85.22B	20.5
argenx SE	ARGX	$64.25B	40.1

The Biotechnology industry average P/E ratio is 12.6x. Avalyn Pharma Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

ARGX

argenx SE

$64.25B

MRNA

Moderna, Inc.

$58.11B

RVMD

Revolution Medicines, Inc.

$45.01B

ONC

BeOne Medicines AG

$40.53B

View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

JNJ

Johnson & Johnson

$663.28B

ABBV

AbbVie Inc.

$453.19B

MRK

Merck & Co., Inc.

$370.89B

UNH

UnitedHealth Group Incorporated

$356.47B

View all Healthcare stocks →

About Avalyn Pharma Inc.

Avalyn Pharma Inc. operates as a clinical-stage biopharmaceutical company developing inhaled medicines to treat rare respiratory diseases, including pulmonary fibrosis and other interstitial lung diseases. The company provides inhaled formulations of oral medicines directly to the lungs. Its current pipeline is focused on treating pulmonary fibrosis. Its products include AP01 and AP02, inhaled formulations of pirfenidone and nintedanib for the treatment of progressive pulmonary fibrosis and idiopathic pulmonary fibrosis; and AP03, a fixed-dose combination of inhaled pirfenidone and nintedanib to deliver dual antifibrotic mechanisms. Avalyn Pharma Inc. was formerly known as Genoa Pharmaceuticals, Inc. and changed its name to Avalyn Pharma Inc. in July 2017. The company was incorporated in 2011 and is based in Boston, Massachusetts.

Visit website →